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Background: Suicide is a worldwide public health concern that claims close to 1 million lives each year. Suicidal
behaviour is a significant risk factor for completed suicide and is much more prevalent than completed suicide.
Many internal and external factors contribute to the risk of suicidal behaviour. Recent research has focused on
biological markers in suicide risk, including brain-derived neurotrophic factor (BDNF). BDNF is a protein involved
in the growth, function, and maintenance of the nervous system. It has been implicated in psychiatric disorders
and suicide. While some evidence suggests that reduced levels of BDNF are associated with suicide, the precise
relationship has yet to be determined. The aim of this study is to review the literature examining the relationship
between levels of BDNF and suicidal behaviour.
Methods: A predefined search strategy will be implemented to search the following electronic databases:
PubMed/MEDLINE, Excerpta Medica Database (EMBASE), PsycINFO, and Cumulative Index to Nursing and Allied
Health Literature (CINAHL) from inception. The articles will be screened by two independent authors (RE and SP)
using predetermined inclusion and exclusion criteria. Discrepancies will be resolved by consensus, or by a third
author (ZS) in cases of disagreement. The primary outcome will be the association between levels of BDNF and
suicidal behaviour. A meta-analysis will be conducted if appropriate. Quality of evidence and risk of bias will
be evaluated.
Discussion: The findings of this review will assist in identifying and treating individuals at increased risk of
suicide.
Systematic review registration: PROSPERO CRD42015015871.
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ProtocolBackground
Suicide is a worldwide public health concern. It claims the
lives of over 800,000 people each year, and the numbers
continue to increase [1]. Suicide has a devastating impact
at a number of levels, including the individual, family,
community, and society. Suicidal behaviour encompasses
a complex set of ideas, plans, and acts intended to end
one’s own life. It occurs 10 to 20 times more often than* Correspondence: samaanz@mcmaster.ca
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unless otherwise stated.completed suicide and is a significant risk factor for com-
pleted suicide in the general population [1,2].
While the causes of suicide are unclear, a number of
internal (biological and psychological) and external (so-
cial and environmental) factors are thought to contribute
to the risk of suicidal behaviour. Internal risk factors
include psychiatric disorders (especially mood disorders),
substance use disorders, chronic illness, and demo-
graphic variables (age and sex) [3]. External factors
include unemployment, unmarried status, and a lack of
social support [2,3]. While having a psychiatric disorder
significantly increases one’s risk of suicide [4], and about
90% of people who attempt or complete suicide have a
psychiatric disorder [3], most individuals with psychiatrichis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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may be a predisposition toward suicidal behaviour inde-
pendent of the underlying psychiatric disorders [2]. As
well, many cases of suicide cannot be explained by the
conventional risk factors proposed by clinical and research
observations. Therefore, the focus has shifted to the inves-
tigation of biological markers in suicide risk, which has
become more common among the recent literature.
The role of neurotrophins has been explored in relation
to psychiatric disorders, including depression, bipolar dis-
order, anxiety, and schizophrenia [5]. Neurotrophins are a
family of proteins that regulate the survival, development,
maintenance, and function of vertebral nervous systems
[6]. Brain-derived neurotrophic factor (BDNF) is the most
abundant member of the neurotrophin family [6] and has
been implicated in both suicide and suicidal behaviour [7].
BDNF is expressed in the brain and in other body tissues
such as skeletal muscle and circulates throughout the
body in the bloodstream [7,8]. When BDNF is released by
a cell, it triggers a cascade of events that lead to neurogen-
esis, nerve growth, neuroplasticity, and neurotransmission
[7]. BDNF is also important in morphological plasticity,
neurite outgrowth, phenotypic maturation, and protein
synthesis for neuron and synaptic functioning [6]. Since
BDNF is intrinsic to these important processes, patho-
logical changes in BDNF levels are likely involved in
neurological deficits that impair one’s ability to adapt to
difficult situations. Altered levels of BDNF may be respon-
sible for the cognitive deficits and altered brain structure
associated with depression, stress, and suicide.
Some studies have linked reduced levels of BDNF to psy-
chiatric disorders and suicide. Low levels of serum BDNF
are associated with a dispositional vulnerability to depres-
sion and with acute depressive states in the general popula-
tion [9]. Lower levels of both serum and plasma BDNF are
associated with major depressive disorder, and serum levels
in particular have been correlated to severity of depression
[10,11]. Stress, which plays an important role in suicidal be-
haviour and constitutes a major risk factor [7,12], is associ-
ated with altered levels of BDNF in the brain [13-16]. But
while brain levels of BDNF are altered in depression and
stress, evidence suggests a differential role of BDNF de-
pending on the location in the brain. Depression and stress
are associated with low levels of BDNF in the hippocampus
and prefrontal cortex but high levels of BDNF in the amyg-
dala and nucleus accumbens [17]. Antidepressants have
been shown to normalize levels of BDNF expression [18].
Postmortem studies of the brains of suicide victims have
revealed abnormally low levels of BDNF and its receptor,
tropomyocin receptor kinase B (TrkB), compared to con-
trols [19,20]. Interestingly, this was true regardless of the
psychiatric diagnosis. Other studies have measured per-
ipheral levels of BDNF in the blood of suicidal individuals.
Deveci and colleagues compared serum BDNF levelsamong suicide attempters, depressed patients, and healthy
controls [21]. Mean serum BDNF was significantly lower
in both the suicidal group and the depressed group com-
pared to the controls. Studies of plasma BDNF have found
decreased levels in suicidal depressed patients compared
with nonsuicidal depressed patients [22,23].
BDNF is a modifiable risk factor for suicidal behaviour.
However, relatively few studies have investigated the re-
lationship between levels of BDNF and suicidal behav-
iour. As well, since BDNF levels are altered in both
depression and suicide, it is unclear whether the differ-
ences are related specifically to suicide. A systematic re-
view is needed in order to summarize the existing
studies and determine whether BDNF levels are in fact
associated with suicidal behaviour, as well as to identify
gaps in the literature that require further research.
Objectives
The objective of this systematic review is to elucidate the
association between levels of BDNF and suicidal behaviour
(including completed suicide, attempted suicide, and sui-
cidal ideation) in an adult population through a methodo-
logical summary of the literature.
The study goals are the following:
1. To investigate the relationship between levels of
BDNF and suicidal behaviour by summarizing
primary studies that have examined this relationship.
2. To combine the results of primary studies in a
statistical manner using meta-analysis, when
appropriate.
3. To critically evaluate the existing literature and
identify which areas require additional research.
Methods/Design
Inclusion and exclusion criteria
This systematic review will include published observa-
tional studies (case–control and cohort studies) of central
and peripheral levels of BDNF (including postmortem
brain tissue, cerebrospinal fluid, plasma, serum, whole
blood, and urine) and suicidal behaviours (including com-
pleted suicide, attempted suicide, and suicidal ideation) in
a population aged 18 and older. Included studies will have
investigated the association between levels of BDNF and
suicidal behaviour by comparing BDNF levels between
groups with and without suicidal behaviour. This review
will include clinical samples as well as community-based
samples. No demographic limitations will be applied apart
from age, and no special populations will be excluded (e.g.
incarcerated individuals, pregnant women, etc.).
Search strategy
All relevant studies will be identified with no language
or time restrictions. The databases to be searched from
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Excerpta Medica Database (EMBASE), and Cumulative
Index to Nursing and Allied Health Literature (CINAHL).
The search strategy (presented in Table 1) will use relevantTable 1 Search strategy for retrieval of relevant articles from
Database Search strategy
MEDLINE (n = 106) 1. exp Suicide/
2. suicid*.mp.
3. exp Self-Injurious Beh
4. (self harm* or self infl
5. automutilat*.mp
6. 1 or 2 or 3 or 4 or 5
7. brain derived neurotr
8. bdnf.mp
9. 7 or 8
10. 6 and 9
EMBASE (n = 366) 1. exp suicidal behaviou
2. suicid*.mp.
3. exp automutilation/
4. (self harm* or self infl
5. 1 or 2 or 3 or 4
6. brain derived neurotr
7. bdnf.mp.
8. 6 or 7
9. 5 and 8
PsycINFO (n = 76) 1. exp Suicide/
2. exp Attempted Suicid
3. exp Suicidal Ideation/
4. suicide*.mp
5. exp Self Injurious Beh
6. (self harm* self injur*
7. 1 or 2 or 3 or 4 or 5 o
8. brain derived neurotr
9. bdnf.mp.
10. 8 or 9
11. 7 and 10
CINAHL (n = 4) 1. MH (“Suicide+”)
2. “suicid*”
3. MH (“Self-Injurious Be
4. “self harm*” OR “self in
5. 1 or 2 or 3 or 4
6. “brain derived neurot
7. “bdnf”
8. 6 or 7
9. 5 and 8
CINAHL, Cumulative Index to Nursing and Allied Health Literature; EMBASE, Excerptkeywords and their associated medical subject headings
(MeSH). A number of different search terms related to
suicidal behaviour that are common in the literature will
be used in order to encompass this broad topic, includingmultiple databases
avior/
ict* or self injur* or self wound* or self mutilat*).mp.
ophic factor.mp. or Brain-Derived Neurotrophic Factor/
r/
ict* or self wound* or self mutilat* or autmutilat*).mp.
ophic factor.mp. or exp brain derived neurotrophic factor/
e/
avior/
or self inflict* or self wound* or self mutilat* or autmutilat*).mp.
r 6
ophic factor.mp. or exp Brain Derived Neurotrophic Factor/
havior”)
jur*” OR “self inflict*” OR “self wound*” OR “self mutilat*” OR “automutil*”
rophic factor”
a Medica Database.
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“self harm*”, “automutilation”, “self inflict*”, and “suicidal
ideation.” These terms will be combined with the term
“brain-derived neurotrophic factor” or “BDNF”. The
search will include titles, abstracts, and keyword fields.
The reference lists from the included articles will be
scanned manually to identify additional studies. The grey
literature will be searched using the ProQuest Disserta-
tions and Theses Database. Reviews, abstracts, and com-
mentaries will be excluded. No language restrictions will
be applied. An experienced health sciences librarian (LB)
was consulted and assisted in the search strategy. A search
alert will be set up to ensure the retrieval of relevant stud-
ies published after the initial search.
Data screening
All citations and abstracts retrieved using the predefined
search strategy (Table 1) will be screened by two raters
(RE and SP) independently. Eligible articles will be iden-
tified using pre-established criteria and retrieved for
full-text review. Disagreements at any point in the re-
view process will be resolved by discussion. In cases
where consensus is not reached, eligibility will be deter-
mined by a third author (ZS). Studies that are ineligible
will be excluded from review. The reasons for exclusion
will be recorded and described in the flow diagram (see
Additional file 1: Figure S1). For each phase of screening,
the Kappa statistic will be used to calculate inter-rater
agreement [24]. The authors of the studies will be con-
tacted for clarification and additional data when necessary.
Data extraction
The two raters (RE and SP) will extract data independently
from the included studies using a pre-established data
extraction form that will be pilot tested beforehand (see
Additional file 2). The raters will obtain the following
information from each study: first author, year of publica-
tion, city and country of publication, article title, journal,
study design, description of sample population, mean age,
ethnicity, and definition of suicidal behaviour. For studies
that include more than one measure of suicidal behaviour,
each measure will be recorded. This will allow for the
combination of studies with the same measures in a meta-
analysis. For example, some studies have used the suicide
item in Hamilton Depression Rating Scale (HDRS), while
others have used the Beck Scale for Suicidal Ideation
(BSS) [25,26]. We will record all measures reported so that
we can combine, for instance, all studies that used the
BSS. We expect most studies to report suicidal behaviour
as a dichotomous measure (e.g. history of suicide attempt
or no history of suicide attempt). However, if studies used
different measurement scales to indicate severity of sui-
cidal behaviour, then we will use a dichotomized outcome
based on the presence of suicidal behaviour, regardless ofseverity. For studies that report multiple time points for
suicidal behaviour (e.g. suicide attempt within the last
month vs. the past 3 months vs. lifetime), all time points
will be recorded. This will allow for the combination of
similar time frames when possible. Information regarding
the BDNF measurements will be obtained, including the
tissue sample in which it was measured, the lab analysis
methods, the mean BDNF levels and standard deviations,
and the unit of measurement used. If relevant, the com-
parison group and any underlying psychiatric disorders
will also be recorded. For each study, primary and second-
ary outcome measures, results, statistical analyses, and
conclusions will be recorded. If any data are missing or in-
complete, authors will be contacted for additional details.
Assessment of quality
The risk of bias of included studies will be assessed by two
independent raters (RE and SP) using the Newcastle-
Ottawa Scale (NOS) [27]. An adapted version of the NOS
will be used, in keeping with previous systematic reviews of
observational studies (see Additional file 3) [28]. This ver-
sion of the NOS contains seven questions in the following
domains: methods for selecting study participants (selection
bias), methods to control for confounding (performance
bias), statistical methods (detection bias), and methods of
exposure and outcome assessment (information bias). Risk
of bias will be assessed on a scale from 0 to 3, where 0 indi-
cates high risk of bias and 3 indicates low risk. Descriptions
and examples of high and low risk of bias are provided.
This adapted NOS also includes categories related to statis-
tical methods, confounding effects, and reporting of miss-
ing data. The Grading of Recommendations, Assessment,
and Evaluation (GRADE) framework will be used to report
the quality of evidence and strength of recommendations
[29]. This framework provides a systematic approach for
considering and reporting risk of bias, imprecision, incon-
sistency, indirectness of study results, and publication bias.
A summary of findings table will be presented to allow for
assessment of confidence in the estimates.
Statistical analyses and heterogeneity
The results of this systematic review will be presented as
a qualitative summary of the literature. When possible,
meta-analyses will be performed. This review will en-
compass a wide variety of studies with different designs,
sample populations, BDNF measurements, and defini-
tions of suicidal behaviour. Clinical and methodological
heterogeneity are expected. Therefore, separate meta-
analyses will be conducted on groups of studies that
share the following characteristics:
1. Study design (e.g. case control vs. cohort)
2. Definition of suicidal behaviour (completed suicide,
attempted suicide, or suicidal ideation)
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plasma, serum, brain tissue)
Meta-analyses will be performed using the extracted
data from groups of studies if the following conditions
are met:
 More than one study is found that share all of the
characteristics listed above
 There are minimal differences among the studies in
other relevant characteristics (such as sample
population)
 Data in each study are available and reported with
sufficient detail.
Heterogeneity will be assessed using the I2 statistic. The
interpretation of the I2 value will be based on the guidelines
in the Cochrane Handbook for Systematic Reviews of Inter-
ventions, which defines 0% to 40% as low heterogeneity,
30% to 60% as moderate heterogeneity, 50% to 90% as sub-
stantial heterogeneity, and 75% to 100% as considerable
heterogeneity [30]. In this study, an I2 value below 50% will
be considered low heterogeneity. The P value from the chi-
squared test will also be taken into consideration, with
significant heterogeneity being defined with a P value below
0.10. Groups of studies in which heterogeneity is found to
be low (I2 < 50%) will be assessed in a combined statistical
manner using meta-analysis. The mean differences (MD) in
the BDNF level between groups with and without suicidal
behaviour will be combined into a summary estimate. Only
adjusted values extracted from the primary studies will be
used. A random-effects model will be implemented, as it
accounts for both within-study and between-study variabil-
ity. As well, a mixed-effects model will be used to examine
the possible mediation effect of BDNF on the relationship
between other variables (including sex, age, and psychiatric
diagnosis) and risk of suicidal behaviour. Sensitivity analysis
will be conducted based on risk of bias; studies with a score
of 0 on the NOS will be excluded to determine whether the
summary estimate stays the same.
The main source of heterogeneity hypothesized is clinical
heterogeneity, resulting from diversity in the populations
being studied. Some studies have derived their samples
from particular clinical populations, such as depressed pa-
tients, while others have sampled populations with a range
of psychiatric diagnoses, or community-based populations.
Since alterations in BDNF levels are linked to psychiatric
disorders, particularly depression, the sample characteristics
could have a significant influence on the associations be-
tween BDNF levels and suicidal behaviour [5,9]. The impli-
cations of this heterogeneity on the interpretation of the
results will be discussed.
In the event that the heterogeneity is too high to allow
for meta-analyses to be performed, the results of thissystematic review will be presented as a narrative sum-
mary of the literature examining the relationship between
levels of BDNF and suicidal behaviour. The included stud-
ies will be synthesized in a comprehensive, up-to-date re-
view of this emerging area of research.
Presenting and reporting of results
This systematic review will be performed and presented
according to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines,
as well as the Meta-analysis of Observational Studies in
Epidemiology (MOOSE) guidelines [31,32]. The article
selection process will be summarized in a flow diagram
(see Additional file 1: Figure S1). The relevant outcomes
and characteristics of each study will be reported in
summary tables. Publication bias will be assessed using
Egger’s plot.
This protocol follows the Preferred Reporting Items
for Systematic Review and Meta-Analysis Protocols
(PRISMA-P) 2015 Statement [33].
Discussion
This systematic review will present evidence from which
conclusions can be made regarding the relationship be-
tween levels of BDNF and suicidal behaviour. It is ex-
pected that an inverse correlation will be found, with
reduced levels of BDNF associated with suicidal behaviour.
The findings of this systematic review will contribute to
our understanding of BDNF as a biological factor involved
in suicide risk, and of suicide pathology more generally.
These findings, as well as the appraisal of the status of the
literature, will be of use to clinicians, in identifying individ-
uals at increased risk of suicide, and researchers, in devel-
oping therapeutic targets.
Additional files
Additional file 1: Figure S1. PRISMA flow diagram.
Additional file 2: Data extraction form.
Additional file 3: Modified NOS.
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